2023 ISAKOS Biennial Congress ePoster
Role of Biophysic Stimulation with Pulsed Electromagnetic Fields on Bone Bruise in Anterior Cruciate Ligament Reconstruction
Vito Gaetano Rinaldi, MD, Bologna ITALY
Iacopo Sassoli, MD, Bologna ITALY
Matteo La Verde, MD, Bologna ITALY
Eugenio Cammisa, MD, Bologna, Bo ITALY
Federico Coliva, MD, Bologna, BO ITALY
Alberto Fogacci, MD, Bologna ITALY
Giada Lullini, MD, PhD, Bologna ITALY
Stefano Zaffagnini, MD, Prof., Bologna ITALY
Giulio Maria Marcheggiani Muccioli, MD, PhD, Associate Professor, Bologna ITALY
Istituto Ortopedico Rizzoli, University of Bologna, Bologna, ITALY
FDA Status Cleared
Summary
A randomized controlled trial on the role of biophysic stimulation with pulsed electromagnetic fields on bone bruise in anterior cruciate ligament reconstruction
ePosters will be available shortly before Congress
Abstract
Introduction
Pulsed electromagnetic fields (iOne®, IGEA S.p.A, Italy) effectiveness in inflammation modulation and articular homeostasis promotion has been widely demonstrated in in-vitro and in-vivo on animal models research.
The primary goal of this study was to evaluate the effectiveness of iOne® in reducing post-operative pain (measured by VAS score) after anterior cruciate ligament (ACL) reconstruction associated with tibial and femoral bone bruise (BB) when applied at least for 4 hours a day, 15 days before and 2 months after surgery.
Secondary goals were quantification of the BB area dimensional reduction (measured by WORMS scale), improvement in knee functional outcomes (measures by IKDC, KOOS and TEGNER scores), and global health condition (measured by SF-12 score).
Materials And Methods
Between 2017 and 2022, 66 patients were recruited. Inclusion criteria were: (1) Patients with complete ACL tear associated with BB, (2) aged between 15 and 55 years with (3) MRI acquired within 21 days from trauma. Were excluded from this study patients with (1) previous surgeries on the affected knee, (2) BMI >30, and (3) multi-ligament or cartilage associate lesions.
Patients were randomized into 2 groups (treated with iOne? and control group) based on sex, BB > or <1 cm, and smoking habits.
PROMs evaluations were made by VAS, TEGNER, SF-12, KOOS and IKDC scores.
Results
Pain evaluated by VAS significantly decreased before surgery (2.16 ± 1.71 – 0.91 ± 1.02, p <0.05) and 12 months after surgery (0.63 ± 0.52 – 0.09 ± 0.30, p <0.05) in the treated group.
TEGNER was not significantly decreased in the treated group.
SF-12 (PCS) significantly decreased before surgery (63 ± 30 – 84 ± 28, p <0.05) and 6 months after surgery (73 ± 24 – 107 ± 19, p <0.05) in the treated group. SF-12 (MCS) was not significantly decreased in the treated group.
KOOS significantly decreased 6 months after surgery (80 ± 14 – 91 ± 5, p <0.05) in the treated group.
IKDC was not significantly decreased in the treated group.
Discussion
Many in-vitro studies demonstrated how iOne® produces a significant increase in proteoglycan and 2A2-adenosine receptors synthesis on neutrophilis, synoviocytes and chondrocytes, promoting new subchondral tissue in animal models.
This in-vivo study on human models confirms the effectiveness of iOne® treatment.
Conclusions
Treatment with pulsed electromagnetic fields has proven to be viable in pre- and post-surgery pain management and in improving and accelerating functional recovery, the return to sport, and BB resorption in patients who had undergone ACL reconstruction associated with BB.